Shopping Cart 0
Cart Subtotal
AED 0

Kamada Ltd (KMDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Kamada Ltd (Kamada) is a biopharmaceutical company that develops, manufactures and markets specialty proteins, specific immunoglobulins and other prescription medicines. Its major products include pulmonary related medicines, immunoglobins, vaccines and critical care medicines. It also offers medicines for the treatment of cystic fibrosis, asthma, heamophilia, rabies, hepatitis B, and other indications. Kamada's pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes and lung transplantation indications. The company distributes its products through a network of distributors in Brazil, Israel, Russia, India and other countries in Eastern Europe, Latin America and Asia regions. Kamada is headquartered in Ness Ziona, Israel.

Kamada Ltd (KMDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kamada Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Brosh Capital Acquires 6.2% Stake in Kamada 11

Partnerships 12

Tetra Bio-Pharma to Enter into Agreement with Kamada 12

Kamada Enters into Agreement with Mount Sinai Acute GvHD International Consortium 13

Kamada Enters into Partnership with BGN Technologies 14

Kamada Expands Partnership with Massachusetts General Hospital 15

Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 16

Kamada Partners with myTomorrows 17

Equity Offering 18

Kamada Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18

Kamada Completes Public Offering Of Shares For USD 59 Million 20

Kamada Ltd-Key Competitors 21

Kamada Ltd-Key Employees 22

Kamada Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 07, 2018: Kamada announces financial results for second quarter and first six months of 2018 24

May 15, 2018: Kamada Reports Financial Results for First Quarter of 2018 26

Feb 07, 2018: Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017 28

Nov 13, 2017: Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017 30

Aug 01, 2017: Kamada Reports Financial Results for Second Quarter and First Six Months of 2017 32

Jul 27, 2017: Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017 34

May 16, 2017: Kamada Reports 2017 First Quarter Financial Results 35

Feb 06, 2017: Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016 37

Corporate Communications 39

Nov 10, 2017: Kamada Announces Nomination of Three New Members to its Board of Directors 39

Sep 18, 2017: Kamada Announces CFO Transition 40

Feb 08, 2017: Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors 41

Clinical Trials 42

May 24, 2017: Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference 42

Other Significant Developments 43

Aug 29, 2018: Kamada provides updated full-year 2018 revenue guidance 43

Aug 16, 2018: Kamada announces the end of the labor strike in the company's manufacturing facility; all employees returned to work 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Kamada Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kamada Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Brosh Capital Acquires 6.2% Stake in Kamada 11

Tetra Bio-Pharma to Enter into Agreement with Kamada 12

Kamada Enters into Agreement with Mount Sinai Acute GvHD International Consortium 13

Kamada Enters into Partnership with BGN Technologies 14

Kamada Expands Partnership with Massachusetts General Hospital 15

Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 16

Kamada Partners with myTomorrows 17

Kamada Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18

Kamada Completes Public Offering Of Shares For USD 59 Million 20

Kamada Ltd, Key Competitors 21

Kamada Ltd, Key Employees 22

Kamada Ltd, Other Locations 23

Kamada Ltd, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Kamada Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Kamada Ltd (Kamada) is a biopharmaceutical company that develops, manufactures and markets specialty proteins, specific immunoglobulins and other prescription medicines. Its major products include pulmonary related medicines, immunoglobins, vaccines and critical care medicines. It also offers medicines for the treatment of cystic fibrosis, asthma, heamophilia, rabies, hepatitis B, and other indications. Kamada's pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes and lung transplantation indications. The company distributes its products through a network of distributors in Brazil, Israel, Russia, India and other countries in Eastern Europe, Latin America and Asia regions. Kamada is headquartered in Ness Ziona, Israel.

Kamada Ltd (KMDA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kamada Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Private Equity 11

Brosh Capital Acquires 6.2% Stake in Kamada 11

Partnerships 12

Tetra Bio-Pharma to Enter into Agreement with Kamada 12

Kamada Enters into Agreement with Mount Sinai Acute GvHD International Consortium 13

Kamada Enters into Partnership with BGN Technologies 14

Kamada Expands Partnership with Massachusetts General Hospital 15

Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 16

Kamada Partners with myTomorrows 17

Equity Offering 18

Kamada Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18

Kamada Completes Public Offering Of Shares For USD 59 Million 20

Kamada Ltd-Key Competitors 21

Kamada Ltd-Key Employees 22

Kamada Ltd-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 07, 2018: Kamada announces financial results for second quarter and first six months of 2018 24

May 15, 2018: Kamada Reports Financial Results for First Quarter of 2018 26

Feb 07, 2018: Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017 28

Nov 13, 2017: Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017 30

Aug 01, 2017: Kamada Reports Financial Results for Second Quarter and First Six Months of 2017 32

Jul 27, 2017: Kamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017 34

May 16, 2017: Kamada Reports 2017 First Quarter Financial Results 35

Feb 06, 2017: Kamada Reports Financial Results for the Fourth Quarter and Full-Year 2016 37

Corporate Communications 39

Nov 10, 2017: Kamada Announces Nomination of Three New Members to its Board of Directors 39

Sep 18, 2017: Kamada Announces CFO Transition 40

Feb 08, 2017: Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors 41

Clinical Trials 42

May 24, 2017: Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference 42

Other Significant Developments 43

Aug 29, 2018: Kamada provides updated full-year 2018 revenue guidance 43

Aug 16, 2018: Kamada announces the end of the labor strike in the company's manufacturing facility; all employees returned to work 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kamada Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Kamada Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kamada Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kamada Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kamada Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Kamada Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Brosh Capital Acquires 6.2% Stake in Kamada 11

Tetra Bio-Pharma to Enter into Agreement with Kamada 12

Kamada Enters into Agreement with Mount Sinai Acute GvHD International Consortium 13

Kamada Enters into Partnership with BGN Technologies 14

Kamada Expands Partnership with Massachusetts General Hospital 15

Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 16

Kamada Partners with myTomorrows 17

Kamada Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 18

Kamada Completes Public Offering Of Shares For USD 59 Million 20

Kamada Ltd, Key Competitors 21

Kamada Ltd, Key Employees 22

Kamada Ltd, Other Locations 23

Kamada Ltd, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Kamada Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.